North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer

Size: px
Start display at page:

Download "North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer"

Transcription

1 THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED WHEN PRINTED Document Control Prepared by Approved by Dr Emma Brown + Changes informed to NMcL Issue date Review date September 2016 Version This version V2.3 ( ) Page 1 of 10

2 General principles THIS DOCUMENT IS Clinical Management Guideline for Initial Diagnosis, pre-treatment Evaluation & Staging All patients (including those who decline, or are considered clinically not suitable for active treatment) should be registered with the appropriate Lung cancer MDT in order to ensure accurate data capture and an opportunity for peer review In advance of any patient being discussed at the specialist Lung Cancer MDT, it is important to have taken steps earliest to establish i) a definitive diagnosis ii) an indication of clinical staging (see page 10) All patients should be referred or made aware earliest to the service Lung Clinical Nurse Specialist for assessment and ongoing specialist advice, education, support and co-ordination of care for both the patient and their relatives throughout the treatment pathway: this is in addition to any other specialist referrals that may also be clinically required depending on individual patient circumstances. Key Points* For all patients either undergoing investigation for, or with a suspected/confirmed diagnosis of lung cancer: The informed wishes of individual patient must direct any decision making with respect to treatment choices within this Clinical Management Plan. The 7th edition of the TNM classification of lung cancer should be used for staging purposes The IASLC** international nodal map should be used in the assessment and staging of lymph node disease MRI or CT scanning of the head should be considered For all patients with a confirmed diagnosis of lung cancer and being considered potentially suitable for radical treatment: A CT scan of the chest, lower neck and upper abdomen with intravenous contrast medium administration should be arranged early in the diagnostic pathway Positron Emission Tomography (PET)-CT scanning should be made available. PET positive mediastinal nodes should be evaluated by further mediastinal sampling The presence of isolated distant metastases/synchronous tumours should be confirmed by biopsy or further imaging Radical treatment should be offered without further mediastinal lymph node sampling if there is no significant uptake in normal sized mediastinal lymph nodes on PET-CT scanning,. The adequacy of diagnostic and staging samples should be considered in the context of selection of patients for targeted therapy. Where there is negligible additional risk to the patient, ensure biopsy samples are taken in adequate numbers and size. Trans-bronchial Needle Aspiration (TBNA) and Endo-bronchial Ultrasound/Endoscopic Ultrasound (EBUS/EUS)-guided TBNA should be used as an initial diagnostic and staging procedure according to findings on CT or PET-CT scans. Confirm negative results obtained by TBNA and EBUS/EUS-guided TBNA by mediastinoscopy and lymph node biopsy where clinically appropriate. *Source: British Thoracic Society Guidelines on the radical management of patients with lung cancer, Thorax, 2010;65 (Supp111) ** IASLC International Association for the Study of Lung Cancer V2.3 ( ) Page 2 of 10

3 Clinical Management Guideline for Radical Treatment - Stage I and II Disease THIS DOCUMENT IS Treatment and pathological stage Adjuvant Treatment Follow-up Initial Evaluation, Clinical Staging, Pre treatment & Evaluation; See (BTS Guideline) on Page 1 Surgical exploration and pt1 T2, N0 (Stage IA/B) pt1-2, NI (Stage IIA-B) pt1-2, N2-3 (Stage IIIA) Complete Incomplete Complete Incomplete Complete Incomplete Consider adjuvant SACT* Radiotherapy Adjuvant SACT* Adjuvant SACT* and radiotherapy Adjuvant SACT* Radiotherapy and SACT* Surveillance Unresectable Radical radiotherapy +/- SACT* For SACT (ie chemotherapy) regimens - see page 7/8 Refused to have surgery or medically inoperable Palliative Radiotherapy Radical Radiotherapy Chemo-radiotherapy Stereotatic Ablative Body Radiotherapy V2.3 ( ) Page 3 of 10

4 THIS DOCUMENT IS Clinical Management Guideline for Radical Treatment - Stage IIIA Disease Initial Evaluation Clinical Stage Pre-Treatment Evaluation Mediastinal Biopsy Initial and Adjuvant Treatment Unresectable/ Medically unfit Treat according to clinical stage Follow-up N2 Node Negative Assess for thoracotomy Surgical plus Mediastinal Lymph Node dissection N0-1 N2 Complete See Page 2 Adjuvant SACT* Refer to BTS Guideline (on Page 1) T1-3, N2 (Stage IIIA) PET Scan Mediastinal nodal sampling Assess medical Fitness N2 Node Positive PS 0 and single station disease Brain imaging PS 0 1 Multistation disease Brain imaging PS 2 Concurrent or sequential chemoradiotherapy* Radical radiotherapy CHART or 55/20 Incomplete Radiotherapy and SACT* Surveillance For SACT (ie chemotherapy) regimens - see page 7/8 Large volume of disease or Poor pulmonary function or Poor PS Palliative radiotherapy +/_ SACT Metastatic disease or pleural effusion See Stage IV Protocol (Page 6) V2.3 ( ) Page 4 of 10

5 THIS DOCUMENT IS Clinical Management Guideline for Radical Treatment - Stage IIIB Disease Initial Evaluation Clinical Stage Treatment Evaluation Primary Treatment Adjuvant Treatment Follow-up T1-3, N3 (Stage IIIB) Assess Volume of Disease & PS PS 0 or 1 PS2 Local symptoms Radical (chemo) radiotherapy* or SACT* +/- high dose palliative radiotherapy Palliative radiotherapy Consider SACT* Refer to BTS Guideline Page 1 Possibly resectable PS 0-1 Induction SACT* Surgical re-evaluation Surgery T4, N0 (Stage IIIB) No pleural effusion Unresectable PS 2 Radical (chemo) radiotherapy or SACT* +/- high dose palliative radiotherapy Radical Radiotherapy PS 0-1 Palliative radiotherapy for local symptoms Best Supportive Care Palliative Care Referral * For SACT (ie chemotherapy) regimens see page 7/8 Surveillance V2.3 ( ) Page 5 of 10

6 THIS DOCUMENT IS Clinical Management Guideline for Initial Treatment - Stage IV Disease Initial Evaluation Clinical Stage Pre-Treatment Evaluation Primary Treatment Adjuvant Treatment Stage IIIB T4 + Pleural or pericardial effusion Pleural or pericardial drainage Cytology negative Treatment according to T and N stage Refer to BTS Guideline Page 1 Cytology positive Local therapy if necessary (e g, pleurodesis, pericardial window) + treatment as for stage IV disease. (below) Stage IV or Malignant Pleural Effusion Performance Status Symptom Evaluation Tumour pathology assessment Palliative SACT* or biological therapy (page 6) Consider 2 nd /3 rd line systemic therapy Palliative Radiotherapy For SACT (ie chemotherapy) regimens - see page 7/8 Best Supportive Care Palliative Care Referral Consider Phase 1 / 2 trials V2.3 ( ) Page 6 of 10

7 Squamous Cell THIS DOCUMENT IS Clinical Management Guideline for Systemic Anti-Cancer Therapy Curative Intent Chemotherapy prior to surgical or sequential chemo-radiotherapy irrespective of EGFR Status Non- Squamous Cell Carboplatin + Gemcitabine Carboplatin [AUC* 5] IV infusion on Day 1 Gemcitabine 1250mg/m² IV infusion on Day(s) 1 & 8 Repeat every 3 weeks/21days Continue to maximum of 4 cycles Cisplatin + Docetaxel Cisplatin 75mg/m² IV infusion on Day 1 Docetaxel 75mg/m² IV infusion on Day 1 Repeat every 3 weeks Continue to a maximum of 4 cycles Concurrent Chemotherapy with radiotherapy [or SOCCAR] Cisplatin + Vinorelbine Cycles 1 (prior to commencement) & Cycle 4 (following after completion) of radiotherapy only Cisplatin 80mg/m² IV Infusion on Day 1 Vinorelbine 25mg/m² (50mg max) IV infusion on Day 1 Vinorelbine 60mg/m² (160mg max) Administered orally on Day 8 Cycle duration: 3 weeks/21days Cycles 2 & 3 (at the same time as receiving radiotherapy) Cisplatin 80mg/m 2 IV Infusion on Day(s) 1 & 8 Vinorelbine 15mg/m 2 IV Infusion on Day(s) 1 & 8 Cycle duration: 3 weeks/21days Cisplatin + Pemetrexed Cisplatin 75mg/m 2 IV infusion on Day 1 Pemetrexed 500mg/m 2 IV Infusion on Day 1 Repeat every 3 weeks Continue to maximum of 4 cycles Note: If Cisplatin contraindicated, replace with Carboplatin [AUC*5] Adjuvant Chemotherapy Cisplatin + Vinorelbine Cisplatin 80mg/m 2 IV Infusion on Day1 Vinorelbine 25mg/m 2 (50mg max) IV infusion on Day 1 Vinorelbine 60mg/m 2 (60mg max.) Administered orally on Day 8 Note: - If Cisplatin contraindicated, replace with Carboplatin [AUC*5] - Vinorelbine may be either IV infusion or Oral at the respective doses. *AUC Area under the Curve (as per Cockroft-Gault equation) SOCCAR - A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypo-fractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer V2.3 ( ) Page 7 of 10

8 Clinical Management Guideline for THIS DOCUMENT IS Patients newly diagnosed requiring palliative SACT At all stages in this flow chart consider patient performance status and participation in clinical trials. 1 st Line 2 nd Line 3 rd Line Adenocarcinoma EGFRm Erlotinib or Afatinib Cisplatin (or Carbo) Pemetrexed Docetaxel +/- nintedonib Adenocarcinoma EGFRw Non-squamous Cisplatin (or Carbo) & Pemetrexed Gemcitabine Docetaxol Progressive Disease on treatment If ALK-1 Translocation Give crizotinib Docetaxel +/- Nintedonib Trials or PAS Scheme Partial Response or Stable Disease on treatment Maintenance pemetrexed Progressive Disease Squamous, & not Otherwise specified Cisplatin (or Carbo) & Gemcitabine or Vinorelbine or Docetaxol Docetaxel No further chemotherapy Outside of trials EGFRm = Mutation EGFRw = Wild Type V2.3 ( ) Page 8 of 10

9 Clinical Management Guideline for Systemic Anti-Cancer Therapy Palliative Intent Afatinib Afatinib 40mg (escalating to 50mg if tolerated) Administered Orally Continue until disease progression or unacceptable toxicity. Carboplatin + Gemcitabine Carboplatin [AUC 5]* by IV infusion on Day 1 Gemcitabine 1250mg/m² by IV infusion on Days 1 & 8 Repeat every 3 weeks/21 days Continue to a maximum of 4 cycles Cisplatin + Pemetrexed Cisplatin 75mg/m² by IV infusion on Day 1 Pemetrexed 500mg/m² by IV infusion on Day 1 Repeat every 3 weeks/21 days Continueto a maximum for 4 cycles. Note: If Cisplatin contraindicated, replace with Carboplatin [AUC*5] Cisplatin + Vinorelbine Cisplatin 80mg/m² IV Infusion on Day 1 Vinorelbine 25mg/m² (max. 50mg) IV infusion on Day 1 Vinorelbine 60mg/m² (max. 160mg) orally on Day 8 Repeat every 3 weeks/21 days Continue to a maximum of? cycles. Note: If Cisplatin contraindicated, replace with Carboplatin [AUC*5] and Vinorelbine may be either IV infusion or Oral at the respective doses. Crizotinib Crizotinib 250mg Administered orally Continue until disease progression or unacceptable toxicity Docetaxel Docetaxel 60-75mg/m² IV infusion on Day 1 Repeat every 3 weeks/21 days Continue until disease progression or unacceptable toxicity. Docetaxel + Nintedanib Docetaxel 60-75mg/m² IV infusion on Day 1 Nintedanib 200mg Administered orally from Days 2 to 21 Repeat every 3 weeks/21days Continue until disease progression or unacceptable toxicity. Erlotinib Erlotinib 150mg Administered orally Continue until disease progression or unacceptable toxicity. Maintenance Pemetrexed 500mg/m² IV infusion on Day 1 Repeated every 3 weeks/21days Continue until disease progression or unacceptable toxicity *AUC Area under the Curve (as per Cockroft-Gault equation) V2.3 ( ) Page 9 of 10

10 Primary Tumour (T) Clinical Management Guideline for THIS DOCUMENT IS AJCC TNM Lung Cancer Staging 7 th Edition 2009 TX T0 Tis T1 T1a T1b T2 T2a T2b T3 T4 Primary tumour cannot be assessed, or tumour proven by the presence of malignant cells in sputum or bronchial washings but not visualized by imaging or bronchoscopy There is no evidence of primary tumour Carcinoma in situ Tumour 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (for example, not in the main bronchus)¹ Tumour 2 cm or less in greatest dimension Tumour more than 2 cm but 3 cm or less in greatest dimension Tumour more than 3 cm but 7 cm or less or tumour with any of the following features (T2 tumours with these features are classified T2a if 5 cm or less): involves main bronchus, 2 cm or more distal to the carina; invades visceral pleura (PL1 or PL2); associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung Tumour more than 3 cm but 5 cm or less in greatest dimension Tumour more than 5 cm but 7 cm or less in greatest dimension Tumour more than 7 cm or one that directly invades any of the following: parietal pleural (PL3), chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus less than 2 cm distal to the carina¹ but without involvement of the carina; or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe Tumour of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, separate tumour nodule(s) in a different ipsilateral lobe Distant Metastasis (M) M0 No distant metastasis M1 Distant metastasis M1a Separate tumour nodule(s) in a contralateral lobe, tumour with pleural nodules or malignant pleural (or pericardial) effusion² M1b Distant metastasis (in extrathoracic organs) Regional Lymph Nodes (N) NX Regional lymph nodes cannot be assessed N0 No regional lymph node metastases N1 Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension N2 Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s) N3 Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s) Notes: ¹ The uncommon superficial spreading tumour of any size with its invasive component limited to the bronchial wall, which may extend proximally to the main bronchus, is also classified as T1a. ² Most pleural (and pericardial) effusions with lung cancer are due to tumour. In a few patients, however, multiple cytopathologic examinations of pleural (pericardial) fluid are negative for tumour, and the fluid is nonbloody and is not an exudate. Where these elements and clinical judgment dictate that the effusion is not related to the tumour, the effusion should be excluded as a staging element and the patient should be classified as M0. V2.3 ( ) Page 10 of 10

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical

More information

An Update: Lung Cancer

An Update: Lung Cancer An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology

More information

Slide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology

Slide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new

More information

Clinical Management Guideline for Small Cell Lung Cancer

Clinical Management Guideline for Small Cell Lung Cancer Diagnosis and Staging: Key Points 1. Ensure a CT scan that is

More information

North of Scotland Cancer Network Clinical Management Guideline for Mesothelioma

North of Scotland Cancer Network Clinical Management Guideline for Mesothelioma THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Mesothelioma [Based on WOSCAN SCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED WHEN PRINTED Document

More information

The 8th Edition Lung Cancer Stage Classification

The 8th Edition Lung Cancer Stage Classification The 8th Edition Lung Cancer Stage Classification Elwyn Cabebe, M.D. Medical Oncology, Hematology, and Hospice and Palliative Care Valley Medical Oncology Consultants Director of Quality, Medical Oncology

More information

AJCC-NCRA Education Needs Assessment Results

AJCC-NCRA Education Needs Assessment Results AJCC-NCRA Education Needs Assessment Results Donna M. Gress, RHIT, CTR Survey Tool 1 Survey Development, Delivery, Analysis THANKS to NCRA for the following work Developed survey with input from partners

More information

North of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix

North of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix THIS DOCUMENT North of Scotland Cancer Network Carcinoma of the Uterine Cervix UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by A Kennedy/AG Macdonald/Others Approved by NOT APPROVED Issue date April

More information

B REAST STAGING FORM. PATHOLOGIC Extent of disease through completion of definitive surgery. CLINICAL Extent of disease before any treatment

B REAST STAGING FORM. PATHOLOGIC Extent of disease through completion of definitive surgery. CLINICAL Extent of disease before any treatment B REAST STAGING FORM CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery (DCIS) (LCIS) (Paget s) mi c a b c d TUMOR SIZE:

More information

B REAST STAGING FORM. PATHOLOGIC Extent of disease through completion of definitive surgery. CLINICAL Extent of disease before any treatment

B REAST STAGING FORM. PATHOLOGIC Extent of disease through completion of definitive surgery. CLINICAL Extent of disease before any treatment B REAST STAGING FORM Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery (DCIS) (LCIS) (Paget s) mi a b c a b c d TUMOR SIZE: S TAGE

More information

GUIDELINES FOR CANCER IMAGING Lung Cancer

GUIDELINES FOR CANCER IMAGING Lung Cancer GUIDELINES FOR CANCER IMAGING Lung Cancer Greater Manchester and Cheshire Cancer Network Cancer Imaging Cross-Cutting Group April 2010 1 INTRODUCTION This document is intended as a ready reference for

More information

Lung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09

Lung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Lung Cancer Imaging Terence Z. Wong, MD,PhD Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Acknowledgements Edward F. Patz, Jr., MD Jenny Hoang, MD Ellen L. Jones, MD, PhD Lung

More information

North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer

North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer THIS DOCUMENT North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer Based on WOSCAN CMG with further extensive consultation within NOSCAN UNCONTROLLED WHEN PRINTED DOCUMENT

More information

Mediastinal Staging. Samer Kanaan, M.D.

Mediastinal Staging. Samer Kanaan, M.D. Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor

More information

Lung 8/7/14. Collecting Cancer Data: Lung NAACCR Webinar Series. August 7, 2014

Lung 8/7/14. Collecting Cancer Data: Lung NAACCR Webinar Series. August 7, 2014 Collecting Cancer Data: Lung 2013 2014 NAACCR Webinar Series August 7, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching

More information

Bronchogenic Carcinoma

Bronchogenic Carcinoma A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most

More information

Non small cell Lung Cancer

Non small cell Lung Cancer Non small cell Lung Cancer The 13th refresher course for residents in radiation oncology Jiraporn Setakornnukul, M.D. Radiation oncology division, Radiology department Siriraj Hospital, Mahidol University

More information

6 th Reprint Handbook Pages AJCC 7 th Edition

6 th Reprint Handbook Pages AJCC 7 th Edition 6 th Reprint Handbook Pages AJCC 7 th Edition AJCC 7 th Edition Errata for 6 th Reprint Table 1 Handbook No Significant Staging Clarifications for 6 th Reprint AJCC 7 th Edition Errata for 6 th Reprint

More information

The Itracacies of Staging Patients with Suspected Lung Cancer

The Itracacies of Staging Patients with Suspected Lung Cancer The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung

More information

Collaborative Stage. Site-Specific Instructions - LUNG

Collaborative Stage. Site-Specific Instructions - LUNG Slide 1 Collaborative Stage Site-Specific Instructions - LUNG In this presentation, we are going to review the AJCC Cancer Staging criteria for the lung primary site. Slide 2 Reading Assignments As each

More information

Role of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City

Role of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Role of Surgery in Management of Non Small Cell Lung Cancer Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Introduction Surgical approach Principle and type of surgery

More information

Surgical management of lung cancer

Surgical management of lung cancer Surgical management of lung cancer Nick Roubos FRACS Cardiothoracic Surgeon Box Hill Hospital, Epworth Eastern Thoracic Oncology Non Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer Mesothelioma Pulmonary

More information

Histopathology of NSCLC, IHC markers and ptnm classification

Histopathology of NSCLC, IHC markers and ptnm classification ESMO Preceptorship on Non-Small Cell Lung Cancer November 15 th & 16 th 2017 Singapore Histopathology of NSCLC, IHC markers and ptnm classification Prof Keith M Kerr Department of Pathology, Aberdeen University

More information

GROUP 1: Peripheral tumour with normal hilar and mediastinum on staging CT with no disant metastases. Including: Excluding:

GROUP 1: Peripheral tumour with normal hilar and mediastinum on staging CT with no disant metastases. Including: Excluding: GROUP 1: Including: Excluding: Peripheral tumour with normal hilar and mediastinum on staging CT with no disant metastases Solid pulmonary nodules 8mm diameter / 300mm3 volume and BROCK risk of malignancy

More information

WHITE PAPER - SRS for Non Small Cell Lung Cancer

WHITE PAPER - SRS for Non Small Cell Lung Cancer WHITE PAPER - SRS for Non Small Cell Lung Cancer I. Introduction This white paper will focus on non-small cell lung carcinoma with sections one though six comprising a general review of lung cancer from

More information

Seventh Edition of the Cancer Staging Manual and Stage Grouping of Lung Cancer. Quick Reference Chart and Diagrams

Seventh Edition of the Cancer Staging Manual and Stage Grouping of Lung Cancer. Quick Reference Chart and Diagrams CHEST Special Features Seventh Edition of the Cancer Staging Manual and Stage Grouping of Lung Cancer Quick Reference Chart and Diagrams Omar Lababede, MD ; Moulay Meziane, MD ; and Thomas Rice, MD, FCCP

More information

NAACCR Webinar Series 1

NAACCR Webinar Series 1 Collecting Cancer Data: Lung 2013 2014 NAACCR Webinar Series August 7, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching

More information

North of Scotland Cancer Network Clinical Management Guideline for Malignant Melanoma

North of Scotland Cancer Network Clinical Management Guideline for Malignant Melanoma Nth of Scotland Cancer Netwk Clinical Management Guideline f Malignant Melanoma Based on WOSCAN CMG with further consultation within NOSCAN UNCONTROLLED WHEN PRINTED Prepared by Approved by Issue date

More information

Collecting Cancer Data: Lung

Collecting Cancer Data: Lung Collecting Cancer Data: Lung NAACCR 2011 2012 Webinar Series 2/2/2012 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this

More information

Lung Cancer Staging: The Revised TNM Classification

Lung Cancer Staging: The Revised TNM Classification Norwegian Society of Thoracic Imaging Oslo, October 2011 Lung Cancer Staging: The Revised TNM Classification Sujal R Desai King s College Hospital, London Lung Cancer The Scale of the Problem Leading cause

More information

Lung /1/16. Please submit all questions concerning webinar content through the Q&A panel. Reminder:

Lung /1/16. Please submit all questions concerning webinar content through the Q&A panel. Reminder: 1 NAACCR 2015-2016 Webinar Series Collecting Cancer Data: Lung NAACCR 2015 2016 Webinar Series Presented by: Angela Martin amartin@naaccr.org Jim Hofferkamp jhofferkamp@naaccr.org Q&A Please submit all

More information

LungStage. Bringing machine learning to Nuclear Medicine and Lung Cancer using Big Data, Machine Learning and Multicenter Studies

LungStage. Bringing machine learning to Nuclear Medicine and Lung Cancer using Big Data, Machine Learning and Multicenter Studies LungStage Bringing machine learning to Nuclear Medicine and Lung Cancer using Big Data, Machine Learning and Multicenter Studies Medical Team: Bram Stieltjes, MD PhD; Alex Sauter, MD; Gregor Sommer, MD;

More information

LUNG STAGING FORM LATERALITY: LEFT RIGHT BILATERAL

LUNG STAGING FORM LATERALITY: LEFT RIGHT BILATERAL LUNG STAGING FORM LATERALITY: LEFT RIGHT BILATERAL ( ) Tx Primary tumor cannot be assessed, or tumor proven by the presence of malignant cells in sputum or bronchial washings but not visualized by imaging

More information

North of Scotland Cancer Network Clinical Management Guideline for Oropharyngeal Cancer

North of Scotland Cancer Network Clinical Management Guideline for Oropharyngeal Cancer Nth of Scotland Cancer Netwk Clinical Management Guideline f Oropharyngeal Cancer UNCONTROLLED WHEN PRINTED Based on NHST CMG with further extensive consultation within NOSCAN DOCUMENT CONTROL Original

More information

Case Conference: Post-Operative Radiotherapy for Non-Small Cell Lung Cancer. Doug Rahn 6/1/12

Case Conference: Post-Operative Radiotherapy for Non-Small Cell Lung Cancer. Doug Rahn 6/1/12 Case Conference: Post-Operative Radiotherapy for Non-Small Cell Lung Cancer Doug Rahn 6/1/12 Outline I. Presentation of Case II. Epidemiology III. Staging IV. Review of Literature V. Recommendations VI.

More information

Lung cancer LUNG CANCER. Box 1 Clinical signs

Lung cancer LUNG CANCER. Box 1 Clinical signs 22 LUNG CANCER Lung cancer Bronchial carcinoma refers to two distinct clinical entities small cell and non-small cell carcinoma. Although these conditions have much in common, with broadly similar presenting

More information

North of Scotland Cancer Network Clinical Management Guideline for Cancer of the Ovary

North of Scotland Cancer Network Clinical Management Guideline for Cancer of the Ovary North of Scotland Cancer Network Cancer of the Ovary Based on WOSCAN CMG with further extensive consultation within NOSCAN UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by NOSCAN Gynaecology Cancer

More information

Lung Cancer Epidemiology. AJCC Staging 6 th edition

Lung Cancer Epidemiology. AJCC Staging 6 th edition Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON

More information

THORACIC MALIGNANCIES

THORACIC MALIGNANCIES THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,

More information

REGIONAL LUNG CANCER GROUP

REGIONAL LUNG CANCER GROUP REGIONAL LUNG CANCER GROUP Document Title Guidelines for the Management of Lung Cancer (Non Small Cell Lung Cancer, Small Cell Lung Cancer and Mesothelioma) Document Date Document Purpose January 2010

More information

FDG PET/CT in Lung Cancer Read with the experts. Homer A. Macapinlac, M.D.

FDG PET/CT in Lung Cancer Read with the experts. Homer A. Macapinlac, M.D. FDG PET/CT in Lung Cancer Read with the experts Homer A. Macapinlac, M.D. Patient with suspected lung cancer presents with left sided chest pain T3 What is the T stage of this patient? A) T2a B) T2b C)

More information

Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón

Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease

More information

Imaging of Lung Cancer: A Review of the 8 th TNM Staging System

Imaging of Lung Cancer: A Review of the 8 th TNM Staging System Imaging of Lung Cancer: A Review of the 8 th TNM Staging System Travis S Henry, MD Associate Professor of Clinical Radiology Cardiac and Pulmonary Imaging Section University of California, San Francisco

More information

LUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University

LUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University LUNG CANCER Agnieszka Słowik, MD Department of Oncology, University Hospital in Cracow Jagiellonian University Epidemiology Most common malignancy worldwide Place of lung cancer among other malignancies

More information

8th Edition of the TNM Classification for Lung Cancer. Proposed by the IASLC

8th Edition of the TNM Classification for Lung Cancer. Proposed by the IASLC 8th Edition of the TNM Classification for Lung Cancer Proposed by the IASLC Introduction Stage classification - provides consistency in nomenclature - improves understanding of anatomic extent of tumour

More information

Lung Cancer Case Study

Lung Cancer Case Study Lung Cancer Case Study Presented by s GP Education Programme 2 Part One Initial presentation 60 year old lady, presents with a 6 week history of right sided chest pain. The pain is like a dull ache, but

More information

North of Scotland Cancer Network Clinical Management Guideline for Metastatic Malignancy of Undefined Primary Origin (MUO)

North of Scotland Cancer Network Clinical Management Guideline for Metastatic Malignancy of Undefined Primary Origin (MUO) North of Scotland Cancer Network Clinical Management Guideline for Metastatic Malignancy of Undefined Primary Origin (MUO) UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Original Prepared by NMcL April 2016

More information

FDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave

FDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER FDG PET/CT is used in all patients with lung cancer who are considered for curative treatment to exclude occult disease.

More information

EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI

EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI Overview Introduction Diagnostic work up Treatment Group 1 Group 2 Group 3 Stage III lung cancer Historically was defined as locoregionally advanced

More information

Tumor Board Discussions: Case 1

Tumor Board Discussions: Case 1 Tumor Board Discussions: Case 1 David S. Ettinger, MD The Alex Grass Professor of Oncology Johns Hopkins University School of Medicine Baltimore, Maryland Case #1 50-year-old Asian female, never smoker

More information

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction

More information

Mediastinal Mysteries: What can be solved with EBUS?

Mediastinal Mysteries: What can be solved with EBUS? Mediastinal Mysteries: What can be solved with EBUS? W. Graham Carlos MD Pulmonary & Critical Care Fellow Indiana University School of Medicine Disclosures None Objectives Introduce you to the technique

More information

Lung Cancer Clinical Guidelines: Surgery

Lung Cancer Clinical Guidelines: Surgery Lung Cancer Clinical Guidelines: Surgery 1 Scope of guidelines All Trusts within Manchester Cancer are expected to follow this guideline. This guideline is relevant to: Adults (18 years and older) with

More information

Audit Report. Lung Cancer Quality Performance Indicators. Patients diagnosed April 2014 March Published: May 2016

Audit Report. Lung Cancer Quality Performance Indicators. Patients diagnosed April 2014 March Published: May 2016 NORTH OF SCOTLAND PLANNING GROUP Lung Cancer Managed Clinical Network Audit Report Lung Cancer Quality Performance Indicators Patients diagnosed April 2014 March 2015 Published: May 2016 Mr Hardy Remmen

More information

Adam J. Hansen, MD UHC Thoracic Surgery

Adam J. Hansen, MD UHC Thoracic Surgery Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered

More information

MEDIASTINAL STAGING surgical pro

MEDIASTINAL STAGING surgical pro MEDIASTINAL STAGING surgical pro Paul E. Van Schil, MD, PhD Department of Thoracic and Vascular Surgery University of Antwerp, Belgium Mediastinal staging Invasive techniques lymph node mapping cervical

More information

Audit Report. Lung Cancer Quality Performance Indicators. Patients diagnosed January December Published: November 2017

Audit Report. Lung Cancer Quality Performance Indicators. Patients diagnosed January December Published: November 2017 Lung Cancer Managed Clinical Network Audit Report Lung Cancer Quality Performance Indicators Patients diagnosed January December 2016 Published: November 2017 Hardy Remmen NOSCAN Lung Cancer MCN Clinical

More information

Lung and Aerodigestive malignancies

Lung and Aerodigestive malignancies Lung and Aerodigestive malignancies Nabil F Saba MD, FACP Professor, Director of the Head and Neck Oncology Program, Winship Cancer Institute Emory University COI I am a consultant for GSK, Merck, BMS,

More information

Management of advanced non small cell lung cancer

Management of advanced non small cell lung cancer Management of advanced non small cell lung cancer Jean-Paul Sculier Intensive Care & Thoracic Oncology Institut Jules Bordet Université Libre de Bruxelles (ULB) www.pneumocancero.com Declaration No conflict

More information

ACRIN NLST 6654 Primary Lung Cancer. F1/F2 Interval: to (mm-dd-yyyy) 1. Date of diagnosis: (mm-dd-yyyy)

ACRIN NLST 6654 Primary Lung Cancer. F1/F2 Interval: to (mm-dd-yyyy) 1. Date of diagnosis: (mm-dd-yyyy) No. F1/F2 Interval: - - 20 to - - 20 (mm-dd-yyyy) 1. Date of diagnosis: - - 20 (mm-dd-yyyy) 2. Samples recorded: ZP Number S-Number 1) 2) 3) 4) (Refer to Form PX, Column 1. In the rare instance of a diagnosis

More information

Surgery for early stage NSCLC

Surgery for early stage NSCLC 1-3 March 2017, Manchester, UK Surgery for early stage NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France what

More information

6 th Reprint Manual Pages AJCC 7 th Edition

6 th Reprint Manual Pages AJCC 7 th Edition 6 th Reprint Manual Pages AJCC 7 th Edition AJCC 7 th Edition Errata for 6 th Reprint Table 1 Manual No Significant Staging Clarifications for 6 th Reprint AJCC 7 th Edition Errata for 6 th Reprint Table

More information

Early and locally advanced non-small-cell lung cancer (NSCLC)

Early and locally advanced non-small-cell lung cancer (NSCLC) Early and locally advanced non-small-cell lung cancer (NSCLC) ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up P. E. Postmus, K. M. Kerr, M. Oudkerk, S. Senan, D. A. Waller, J.

More information

Dr. Andres Wiernik. Lung Cancer

Dr. Andres Wiernik. Lung Cancer Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional

More information

LYMPHATIC DRAINAGE IN THE HEAD & NECK

LYMPHATIC DRAINAGE IN THE HEAD & NECK LYMPHATIC DRAINAGE IN THE HEAD & NECK Like other parts of the body, the head and neck contains lymph nodes (commonly called glands). Which form part of the overall Lymphatic Drainage system of the body.

More information

Single Technology Appraisal (STA)

Single Technology Appraisal (STA) Single Technology Appraisal (STA) Durvalumab for maintenance treatment of locally advanced unresectable non-small cell lung cancer that has not progressed after platinum-based chemoradiation therapy Response

More information

Case Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma.

Case Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma. Case Scenario 1 An 89 year old male patient presented with a progressive cough for approximately six weeks for which he received approximately three rounds of antibiotic therapy without response. A chest

More information

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER 10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg

More information

Lung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD

Lung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive

More information

Combined modality treatment for N2 disease

Combined modality treatment for N2 disease Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical

More information

ADJUVANT CHEMOTHERAPY...

ADJUVANT CHEMOTHERAPY... Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED

More information

The 7th Edition of TNM in Lung Cancer.

The 7th Edition of TNM in Lung Cancer. 10th European Conference Perspectives in Lung Cancer. Brussels, March 2009. The 7th Edition of TNM in Lung Cancer. Peter Goldstraw, Consultant Thoracic Surgeon, Royal Brompton Hospital, Professor of Thoracic

More information

Lung cancer. The diagnosis and treatment of lung cancer. Issued: April NICE clinical guideline 121. guidance.nice.org.

Lung cancer. The diagnosis and treatment of lung cancer. Issued: April NICE clinical guideline 121. guidance.nice.org. Lung cancer The diagnosis and treatment of lung cancer Issued: April 2011 NICE clinical guideline 121 guidance.nice.org.uk/cg121 NICE has accredited the process used by the Centre for Clinical Practice

More information

Lung Carcinoid Tumor Early Detection, Diagnosis, and Staging

Lung Carcinoid Tumor Early Detection, Diagnosis, and Staging Lung Carcinoid Tumor Early Detection, Diagnosis, and Staging Detection and Diagnosis Catching cancer early often allows for more treatment options. Some early cancers may have signs and symptoms that can

More information

Radiological staging of lung cancer. Shukri Loutfi,MD,FRCR Consultant Thoracic Radiologist KAMC-Riyadh

Radiological staging of lung cancer. Shukri Loutfi,MD,FRCR Consultant Thoracic Radiologist KAMC-Riyadh Radiological staging of lung cancer Shukri Loutfi,MD,FRCR Consultant Thoracic Radiologist KAMC-Riyadh Bronchogenic Carcinoma Accounts for 14% of new cancer diagnoses in 2012. Estimated to kill ~150,000

More information

According to the current International Union

According to the current International Union Treatment of Stage II Non-small Cell Lung Cancer* Walter J. Scott, MD, FCCP; John Howington, MD, FCCP; and Benjamin Movsas, MD Based on clinical assessment alone, patients with stage II non-small cell

More information

The International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements

The International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements Page 1 Contents 1.1. Registration... 2 1.2. Patient Characteristics... 3 1.3. Laboratory Values at Diagnosis... 5 1.4. Lung Cancers with Multiple Lesions... 6 1.5. Primary Tumour Description... 10 1.6.

More information

PET CT for Staging Lung Cancer

PET CT for Staging Lung Cancer PET CT for Staging Lung Cancer Rohit Kochhar Consultant Radiologist Disclosures Neither I nor my immediate family members have financial relationships with commercial organizations that may have a direct

More information

RTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman

RTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG

More information

Guideline for the Management of Vulval Cancer

Guideline for the Management of Vulval Cancer Version History Guideline for the Management of Vulval Cancer Version Date Brief Summary of Change Issued 2.0 20.02.08 Endorsed by the Governance Committee 2.1 19.11.10 Circulated at NSSG meeting 2.2 13.04.11

More information

MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER

MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo

More information

Charles Mulligan, MD, FACS, FCCP 26 March 2015

Charles Mulligan, MD, FACS, FCCP 26 March 2015 Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening

More information

Lung Cancer Very common Very lethal Median age of diagnosis i approximately 70 years, but affects all ages In the United States, the highest incidence

Lung Cancer Very common Very lethal Median age of diagnosis i approximately 70 years, but affects all ages In the United States, the highest incidence LUNG CANCER 2010 Mark B. Stoopler, M.D. Division of Medical Oncology Lung Cancer Very common Very lethal Median age of diagnosis i approximately 70 years, but affects all ages In the United States, the

More information

Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016

Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,

More information

Lung Cancer Clinical Data Standards

Lung Cancer Clinical Data Standards For reference only Do Not Use For more information, contact; cdsis@nhs.net Lung Cancer Clinical Data Standards June 2008 National Clinical Dataset Development Programme (NCDDP) Support Team Information

More information

Neues von der IASLC - Proposals zur 8ten Edition der TNM Klassifikation für das Lungenkarzinom. J. Pfannschmidt

Neues von der IASLC - Proposals zur 8ten Edition der TNM Klassifikation für das Lungenkarzinom. J. Pfannschmidt Neues von der IASLC - Proposals zur 8ten Edition der TNM Klassifikation für das Lungenkarzinom J. Pfannschmidt Immunhistochemie durchgängig zur Klassifizierung Integration der molekularen Analyse Neuklassifizierung

More information

For personal use only. Not to be reproduced without permission of the editor

For personal use only. Not to be reproduced without permission of the editor For personal use only. Not to be reproduced without permission of the editor (permissions@pharmj.org.uk) An overview of lung cancer November is Lung Cancer Awareness Month. With public smoking bans springing

More information

Thoracic Surgery; An Overview

Thoracic Surgery; An Overview Thoracic Surgery What we see Thoracic Surgery; An Overview James P. Locher, Jr, MD Methodist Cardiovascular and Thoracic Surgery Lung cancer Mets Fungus and TB Lung abcess and empyema Pleural based disease

More information

Management of Lung Cancer in Older Adults

Management of Lung Cancer in Older Adults Management of Lung Cancer in Older Adults Arti Hurria, MD; Mark G. Kris, MD ABSTRACT Lung cancer is the leading cause of cancer death in the United States. At the time of diagnosis, most patients are older

More information

3/30/2009 Lung Cancer Deaths 2008 Lung Cancer Deaths Lung Cancer Deaths--Males Males 5

3/30/2009 Lung Cancer Deaths 2008 Lung Cancer Deaths Lung Cancer Deaths--Males Males 5 LUNG CANCER 2009 Mark B. Stoopler, M.D. Division of Medical Oncology Very common Very lethal Lung Cancer Median age of diagnosis approximately 70 years, but affects all ages(even pediatric!) Advances in

More information

Impact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer

Impact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer Impact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer Jakob R. Izbicki, MD, Bernward Passlick, MD, Ortrud Karg, MD, Christian Bloechle, MD, Klaus Pantel, MD, Wolfram

More information

Lung Cancer Incidence 2008 Lung Cancer Deaths-Males 2008 Incidence Total U.S.(all types): 1,437,180 Lung Cancer Deaths-Females Lung cancer 215,000(15%

Lung Cancer Incidence 2008 Lung Cancer Deaths-Males 2008 Incidence Total U.S.(all types): 1,437,180 Lung Cancer Deaths-Females Lung cancer 215,000(15% Multidisciplinary approach 2009 Mark B. Stoopler, M.D. Division of Medical Oncology Neurology Neurosurgery Orthopedic surgery General surgery Vascular surgery Gastroenterology Cardiology Lung Cancer Very

More information

Special Treatment Issues in Non-small Cell Lung Cancer

Special Treatment Issues in Non-small Cell Lung Cancer CHEST Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER, 3RD ED: ACCP GUIDELINES Special Treatment Issues in Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College

More information

Treatment of oligometastatic NSCLC

Treatment of oligometastatic NSCLC Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic

More information

Staging of lung cancer provides a common language

Staging of lung cancer provides a common language The 1997 International Staging System for Non-Small Cell Lung Cancer* Have All the Issues Been Addressed? Swan S. Leong, MD; Caio M. Rocha Lima, MD; Carol A. Sherman, MD; and Mark R. Green, MD The International

More information

Lung Cancer. Trusted Information to Help Manage Your Care from the American Society of Clinical Oncology

Lung Cancer. Trusted Information to Help Manage Your Care from the American Society of Clinical Oncology Lung Cancer Trusted Information to Help Manage Your Care from the American Society of Clinical Oncology ABOUT ASCO The American Society of Clinical Oncology (ASCO) is the world s leading professional organization

More information

Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer

Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer Dr Richard Booton PhD FRCP Lead Lung Cancer Clinician, Consultant Respiratory Physician & Speciality Director Manchester University NHS

More information

Tumours of the Oesophagus & Gastro-Oesophageal Junction Histopathology Reporting Proforma

Tumours of the Oesophagus & Gastro-Oesophageal Junction Histopathology Reporting Proforma Tumours of the Oesophagus & Gastro-Oesophageal Junction Histopathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.01). S1.01 Identification Family name Given

More information

Table 1 Major Classifications of Lung Cancer. Non Small Cell Lung Cancer Adenocarcinoma

Table 1 Major Classifications of Lung Cancer. Non Small Cell Lung Cancer Adenocarcinoma VIII LUNG CANCER Jeffrey Crawford, m.d. Definition and Classifications Bronchogenic carcinoma of the lung lung cancer comprises a group of malignant neoplasms that arise from bronchial epithelium. The

More information